Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 339-345

  Wu, Yi Long ^a   Kim, Joo Hang ^b   Park, Keunchil ^c   Zaatar, Adel ^d   Klingelschmitt, Gaëlle ^e   Ng, Christina ^f  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Yonsei University College of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Gleneagles Medical Centre   (Malaysia)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f Sunway Medical Centre   (Malaysia)

Author keywords

Asian patients; Erlotinib; Maintenance therapy; Non small cell lung cancer; NSCLC; Phase III trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ERLOTINIB; PLACEBO;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863780354     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.012     Document Type: Article

References (30)

1. Socinski M.A., Morris D.E., Masters G.A., Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003, 123(1 Suppl.):226S-243S. American College of Chest Physicians.
2. Park J.O., Kim S.W., Ahn J.S., Suh C., Lee J.S., Jang J.S., et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J Clin Oncol 2007, 25:5233-5239.
3. Fidias P.M., Dakhil S.R., Lyss A., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2008, 27:591-598.
4. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind phase 3 study. Lancet 2009, 374:1432-1440.
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Belani C.P., Liao J. Maintenance therapy for non-small-cell lung cancer. Lancet 2010, 375:281-282.
7. Reck M., van Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
8. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
9. Belani C.P., Schreeder M.T., Steis R.G., Guidice R.A., Marsland T.A., Butler E.H., et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer. A multicenter phase 2 study. Cancer 2008, 113:2512-2517.
10. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373:1525-1531.
11. Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
12. Perol M., Chouaid C., Milleron B.J., Gervais R., Barlesi F., Westeel V., et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010, 28(15 Suppl.):540s. [Abstract 7507].
13. Paz-Ares L.G., De Marinis F., Dediu M., Thomas M., Pujol J., Bidoli P., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13:247-255.
14. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
15. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70. on behalf of the ESMO Guidelines Working Group.
16. Ramalingam S., Sandler A.B. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 2006, 11:655-665.
17. Shepherd F., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
18. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
19. Brugger W., Triller N., Blasinka-Morawiec S., Curescu S., Sakalauskas R., Manikhas G.M., et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:4113-4120.
20. Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006, 1:847-855.
21. Mok T., Wu Y.-L., Au J.S.-K., Zhou C., Zhang L., Perng R.P., et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:1609-1615.
22. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
23. Wu J.-Y., Shih J.-Y., Chen K.-Y., Yang C.-H., Yu C.-J., Yang P.-C. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine 2011, 90:159-167.
24. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
25. Kosaka T., Yatabe Y., Onozato T., Mitsudomi T. Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma. J Clin Oncol 2007, 25(Suppl. 18):402S. [Abstract 7574].
26. Wu Y.-L., Zhong W.-Z., Li L., Zhang X.T., Zhang L., Zhou C.C., et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007, 2:430-439.
27. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
28. Mok T., Wu Y.-L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
29. Murray S., Dahabreh I.J., Linardou H., Manoloukos M., Bafaloukos D., Kosmidis P. Somatic mutations of the tyrosine-kinase domain of epidermal growth factor receptor and tyrosine-kinase inhibitor response to TKIs in non-small-cell lung cancer: an analytical database. J Thorac Oncol 2008, 3:832-839.
30. Zhou C., Wu Y-L., Chen G., Feng J., Liu X., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.